- Udyam number
- UDYAM-MH-33-0181756

About Kangrin and Boqe Pharmaceutical Private Limited
Data last updated:
Kangrin and Boqe Pharmaceutical Private Limited is a private limited company based in Thane, Maharashtra, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 28 November 2003 and has been in existence for over 23 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24231MH2003PTC143320. Its GSTIN is 27AABCL0455G2ZQ (Maharashtra). The company holds 3 GST registrations, of which 2 are active.
The company has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹5 Lakh. It is led by directors including Sudip Paul and Ashish Shrimanth Ghosh.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at 212 Blossom Chsraheja Complex Kalyan West, Thane, Maharashtra, India.
As per the financials filed for FY 2024, the company reported a revenue of ₹12.19 Cr, a growth of 39% compared to the previous year. For the same year it recorded a net profit of ₹8.69 Lakh (net margin 0.7%) and EBITDA of ₹12.81 Lakh (EBITDA margin 1.1%). Revenue has grown at a compounded annual rate (CAGR) of 252% over three years and 216% over five years.
As per MCA filings, the company has open charges of ₹4 Cr on record. Court records list 2 cases involving the company, including 2 filed by the company.
Kangrin and Boqe Pharmaceutical Private Limited is registered as an MSME under the Udyam registration framework (Reg. No. UDYAM-MH-33-0181756). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website loguslabortriesindia.co.in.
Company details
Recognitions & Rankings of Kangrin and Boqe Pharmaceutical
Contact details
Kangrin and Boqe Pharmaceutical Private Limited's registered office is in Thane, Maharashtra. Its website is loguslabortriesindia.co.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address212 Blossom Chsraheja Complex Kalyan West, Thane, Maharashtra, India
- IndustryPharma, API Manufacturers, Drug Formulation & Development
To see the full contact details of Kangrin and Boqe Pharmaceutical Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Kangrin and Boqe Pharmaceutical is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Kangrin and Boqe Pharmaceutical Private Limited, buy the company report.
Financials of Kangrin and Boqe Pharmaceutical Private Limited
FY 2024 filings availableKangrin and Boqe Pharmaceutical Private Limited reported revenue of ₹12.19 Cr (up 39% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 216% over five years, including 39% growth in the latest year. EBITDA rose 112% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹12.81 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹8.69 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 1.1% | ||||
| Net Profit Margin | 0.7% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Kangrin and Boqe Pharmaceutical Private Limited, buy the company report.
Board of directors of Kangrin and Boqe Pharmaceutical Private Limited
Kangrin and Boqe Pharmaceutical has 3 current directors and 7 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sudip Paul | Director | 28 Nov 2003 | 22 Years 11 Months | Current |
| Ashish Shrimanth Ghosh | Director | 25 Jan 2021 | 5 Years 9 Months | Current |
| Nilesh Pravin Lokhande | Additional Director | 20 May 2025 | 1 Years 5 Months | Current |
Peer comparison
Kangrin and Boqe Pharmaceutical Private Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Vesta Pharmachem Private Limited | ₹12.29 Cr (FY 2025) | -9.0% | Surat, Gujarat, India | |||
| Madhav Nirman Private Limited | ₹12.26 Cr (FY 2025) | 26.0% | Dehradun, Uttarakhand, India | |||
| Kangrin and Boqe Pharmaceutical Private Limitedthis company | ₹12.19 Cr (FY 2024) | ₹8.69 Lakh | 0.7% | 39.0% | Thane, Maharashtra, India | |
| Shilasagaram Enterprises Private Limited | ₹12.18 Cr (FY 2024) | -9.0% | Hyderabad, Telangana, India | |||
| Slava Therapeutics Private Limited | ₹12.14 Cr (FY 2020) | 138.0% | Hyderabad, Telangana, India | |||
| Nandan Pharma Private Limited | ₹12.12 Cr (FY 2024) | 8.0% | Thane, Maharashtra, India |
To see the full peer comparison of Kangrin and Boqe Pharmaceutical Private Limited, buy the company report.
Auditor
Kangrin and Boqe Pharmaceutical Private Limited is audited by Girish Tanwani & Associates for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Girish Tanwani & Associates | FY 2023 | 145240 |
Shareholding
The shareholding of Kangrin and Boqe Pharmaceutical Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Kangrin and Boqe Pharmaceutical Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 20 Jun 2025 | 101139261 | Canara Bank | ₹4 Cr | Open |
Total charge records: 1 View all charges
Legal cases
Kangrin and Boqe Pharmaceutical Private Limited has 2 court cases on record: 2 filed by Kangrin and Boqe Pharmaceutical. All cases are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 2 | 0 | 0 |
Cases on record (1 of 2)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Chennai, Tamil Nadu | Criminal miscellaneous application | Filed by the company | Disposed |
To see the full case history of Kangrin and Boqe Pharmaceutical Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Kangrin and Boqe Pharmaceutical Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Kangrin and Boqe Pharmaceutical Private Limited has 1 active EPFO establishment as of Nov 18, 2026.
GST
Kangrin and Boqe Pharmaceutical has 3 GST registrations: 2 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AABCL0455G2ZQ | Maharashtra | Active | 09 Oct 2023 |
| 18AABCL0455G1ZQ | Assam | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Kangrin and Boqe Pharmaceutical Private Limited, buy the company report.
Recent activity
Kangrin and Boqe Pharmaceutical Private Limited has 10 board changes on record since 2003: 3 appointments and 7 cessations. The latest: Nilesh Pravin Lokhande was appointed as Additional Director on 20 May 2025.
2 earlier events are in the company report.
Frequently asked questions
Kangrin and Boqe Pharmaceutical is an active private limited company based in Thane, Maharashtra, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 28 November 2003 (23+ years old) and is registered under CIN U24231MH2003PTC143320.
Kangrin and Boqe Pharmaceutical has 3 current directors:
- Sudip Paul - Director
- Ashish Shrimanth Ghosh - Director
- Nilesh Pravin Lokhande - Additional Director
The latest financial statements of Kangrin and Boqe Pharmaceutical on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Kangrin and Boqe Pharmaceutical is 27AABCL0455G2ZQ, registered in Maharashtra. The company has 3 GST registrations in all, of which 2 are active and 1 is cancelled or inactive. Other active GSTINs include 18AABCL0455G1ZQ (Assam).
The CIN (Corporate Identification Number) of Kangrin and Boqe Pharmaceutical is U24231MH2003PTC143320. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Kangrin and Boqe Pharmaceutical has 2 court cases on record: 2 filed by the company.
Kangrin and Boqe Pharmaceutical was incorporated on 28 November 2003, making it 23+ years old. It is registered with the Registrar of Companies, Mumbai.
The peers of Kangrin and Boqe Pharmaceutical by revenue are Vesta Pharmachem Private Limited, Madhav Nirman Private Limited, Shilasagaram Enterprises Private Limited, Slava Therapeutics Private Limited, Nandan Pharma Private Limited, all in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading).
Nilesh Pravin Lokhande was appointed as Additional Director on 20 May 2025. Sudip Paul ceased to be Director on 20 May 2025. Samim Noormohmmed Samari ceased to be Director on 01 Feb 2023. Kangrin and Boqe Pharmaceutical has 10 board changes on record in total.
Yes, Kangrin and Boqe Pharmaceutical is registered as an MSME under Udyam registration (number: UDYAM-MH-33-0181756).
Kangrin and Boqe Pharmaceutical can be reached through the website loguslabortriesindia.co.in. Its registered office is in Thane, Maharashtra, India.

